NanoMedSyn

NanoMedSyn has a breakthrough technology platform of proprietary ligands. These ligands, named AMFA (for Analogues of Mannose 6-phosphate Functionalized on Aglycone position), bind to a cell membrane receptor, the mannose 6-phosphate receptor (M6PR). This ubiquitous receptor is a key receptor for cell uptake leading to endo-lysosomal delivery. Our studies demonstrated that AMFA conjugation on therapeutic agents enhances both cell uptake and efficacy. ​ ​

Applications. The ligands have been conjugated to enzymes, nanoparticles or antibodies. AMFA-grafting to enzymes is particularly appropriate for lysosomal storage disorders, where an enzyme is deficient in lysosome. For nanoparticles, the ligands are attractive to target several organs including prostate and muscles. Onto therapeutic antibodies, AMFA gives a new degradative function (see Figure). At first, the antibody-AMFA binds to its antigen (1). Then, AMFA recognizes M6PR (2), which promotes the cell uptake (3). In acidic endosomes, the antigen is dissociated from the antibody-AMFA (4). The antigen will be then degraded in lysosomes (5) whereas the antibody-AMFA is recycled out of the cell (6). By this way, the antibody-AMFA can perform multiple cycles of antigen degradation.​ ​

The business model of NanoMedSyn is to develop its delivery platform of therapeutics through research collaborations and licensing agreements with pharmaceutical and biotech partners. ​